Welcome to our dedicated page for CDT Equity news (Ticker: CDT), a resource for investors and traders seeking the latest updates and insights on CDT Equity stock.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company whose news flow reflects its focus on AI-enabled drug repurposing, solid-form chemistry, and capital-efficient asset development. Originally operating as Conduit Pharmaceuticals Inc., the company has reported a series of strategic updates as it reshapes itself into a platform centered on high-potential therapeutic assets and intellectual property-led partnerships.
News about CDT often highlights progress in its clinical and pre-clinical programs, particularly around glucokinase activators such as AZD1656 and AZD5658. The company has announced AI-driven discoveries of new biological targets and indications, pre-clinical study results that support these findings, and the filing of new patent applications for key assets and combinations. These items provide insight into how CDT uses artificial intelligence and algorithmic analysis to expand the potential uses of existing compounds.
Another recurring theme in CDT’s news is collaboration. Press releases describe partnerships with Sarborg for AI-powered disease mapping and diagnostic tools, and a joint development agreement with Manoira to evaluate AZD1656 and AZD5658 in animal health indications. Updates on these collaborations can include study plans, cross-species data generation, and implications for both human and veterinary applications.
CDT also issues news on corporate and financial developments. Examples include the adoption and execution of a cryptocurrency-based treasury reserve strategy focused on Bitcoin, board decisions on reverse stock splits, and governance matters documented in SEC-related announcements. Together, these updates offer a view into how the company manages its capital structure while pursuing IP-led licensing and out-licensing opportunities.
Investors and observers who follow CDT’s news can monitor developments in its AI-guided pipeline, patent portfolio, partnerships, and treasury strategy, all of which are central to the company’s stated goal of advancing and monetizing biopharmaceutical assets.
CDT (Nasdaq: CDT) notes Sarborg Limited's expansion of its AI Signature Agent platform beyond pharmaceuticals into bacteria and agrochemicals. CDT holds a 20% equity stake in Sarborg. Sarborg has curated ~4,500 agrochemical and ~1,600 bacterial signatures, supporting multi‑sector scaling.
CDT says this extension broadens Sarborg's addressable markets and gives public investors exposure to its private AI signature intelligence development.
CDT (Nasdaq: CDT) agreed to acquire a 20% equity stake in Sarborg, an agentic AI signature intelligence business, for $115,000,000 settled via issuance of 598,005 new common shares and 109,978,918 pre-funded warrants, subject to shareholder approval. A further $8,000,000 deferred payment is payable upon completion of future fundraising. The deal deepens an existing collaboration focused on signature-led analysis and solid-form intellectual property, expanding CDT’s exposure beyond pharmaceuticals and aligning strategic capabilities between the companies.
CDT (Nasdaq: CDT) announced on January 2, 2026 that it has engaged NJS Foresight Bio-Advisory to identify, source and support execution of out-licensing opportunities for selected assets in its solid-form patent portfolio.
The engagement leverages NJS Foresight's >20 years of out-licensing experience and principal Dr. Nicholas J. Sarlis's clinical and pharma background. CDT's solid-form portfolio includes cocrystals and salts designed to improve solubility, bioavailability and delivery modes and carries up to 20 years of patent protection, enabling potential lifecycle extension for marketed products facing patent cliffs.
CDT said it will target licensing and royalty transactions as companies respond to patent expirations, consolidation and AI-driven adoption across biopharma.
CDT Equity (Nasdaq: CDT) on October 17, 2025 acquired 9.25648743 Bitcoin (BTC) for an aggregate purchase price of $1,005,000 (gross of fees) at an average price of $108,301.75 per BTC.
Following the purchase, CDT’s total Bitcoin holdings are 17.9090111 BTC. The company described the transaction as part of its cryptocurrency treasury reserve strategy to diversify the balance sheet and pursue long-term shareholder value through disciplined accumulation of digital assets.
CDT Equity (Nasdaq: CDT) approved a 1-for-8 reverse stock split, effective Oct 10, 2025 at 5:00 pm ET, with post-split trading expected on Oct 13, 2025 on Nasdaq under the existing ticker CDT.
As of the Effective Time, every eight pre-split shares will be combined into one share, reducing outstanding common stock to approximately 1,352,448 shares. Par value remains $0.0001. Equity awards, convertible securities, warrants, and plan reserves will be proportionally adjusted. Fractional shares will not be issued; holders entitled to fractions will receive a proportional cash payment. The new CUSIP will be 20678X403. The board said the split is expected to increase the amount of funds the company might be able to raise. VStock Transfer, LLC will act as exchange agent.
CDT Equity (Nasdaq: CDT) has announced its entry into cryptocurrency investment with the purchase of 8.65252366 Bitcoin (BTC) for $1 million, at an average price of $115,285 per BTC. This strategic move marks the company's first step in implementing its cryptocurrency treasury reserve strategy.
The initiative aims to diversify CDT's balance sheet and enhance financial resilience while aligning with growing institutional adoption of digital assets. CFO James Bligh indicated that the company continues to evaluate asset allocation to optimize its treasury portfolio and shareholder returns.
CDT Equity (NASDAQ:CDT) has announced its Board's approval of a cryptocurrency-based treasury reserve strategy to diversify its balance sheet management approach. The company will partner with Sarborg to develop an AI-led system for cryptocurrency market evaluation, featuring real-time analytics and automated execution systems.
The decision follows a strategic review of the cryptocurrency and stablecoin market, including consultations with third-party experts and stakeholders. CDT currently has 3,382,025 shares of common stock outstanding, with 250,000,000 authorized shares. The company continues to fund operations through its ATM facility with A.G.P./Alliance Global Partners while maintaining focus on its Phase-2 ready pharmaceutical pipeline.
CDT Equity (NASDAQ:CDT) has announced a significant breakthrough in its AI-driven drug repurposing strategy. The company, in collaboration with Sarborg, has successfully identified a new biological target and novel therapeutic indication for its lead program AZD1656 through AI-powered disease mapping analysis of over 800 disease signatures.
The company has validated this discovery through successful pre-clinical studies, confirming the AI algorithm's findings. Based on these positive results, CDT plans to initiate additional pre-clinical studies to fully explore the potential of this new therapeutic pathway. The discovery represents a validation of CDT's transition to a lean, disease-agnostic model driven by data-based insights.
Conduit Pharmaceuticals (NASDAQ:CDT) announced its intention to rebrand as CDT Equity Inc., reflecting its evolution into a data-driven biotech development platform. The company leverages artificial intelligence, solid-form chemistry, and asset repositioning to accelerate therapeutic treatment development.
CDT's strategy focuses on unlocking value from clinical-stage compounds with strong Phase I safety data, particularly those deprioritized by larger pharmaceutical companies. Through their Cambridge facility's advanced co-crystallization technologies, they have successfully extended patent life of certain drugs by up to 20 years. The company's pipeline targets inflammatory and autoimmune disorders, male infertility, dermatology, and animal health.
Key partnerships include Sarborg for AI-powered disease mapping and Manoira for animal health market expansion. The company is also evaluating a cryptocurrency treasury reserve strategy.
Conduit Pharmaceuticals (Nasdaq: CDT) has engaged a third-party consultant to evaluate the potential implementation of a partial cryptocurrency treasury reserve strategy. The consultant brings extensive cryptocurrency expertise and has contributed to platforms like CoinDesk.
This initiative aims to explore capital diversification opportunities while maintaining the company's core focus on pharmaceutical development. The move follows Conduit's technology-led approach and recent collaboration with Sarborg, positioning the company at the intersection of pharma, technology, and digital finance.
The company believes a partial cryptocurrency reserve could provide long-term optionality and diversified capital utility, while continuing its focus on AI-driven pharmaceutical development and IP protection in autoimmune and rare diseases.